Nuvectis initiates phase 1b program for cancer drug NXP900

FORT LEE, N.J. - Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical-stage biopharmaceutical company with a market capitalization of $153 million, announced Monday the initiation of its Phase 1b program for NXP900, following the successful completion of a dose escalation study in patients with advanced solid tumors and a clinical drug-drug interaction study in healthy volunteers. According to InvestingPro data, the stock has recently seen significant movement, declining nearly 18% over the past week.

The Phase 1b program includes a single agent component that is now underway and a combination component expected to begin later this year. The single agent study will evaluate NXP900 in patients with specific genetic alterations, including YES1 amplified or FAT1 mutated non-small cell lung cancer (NSCLC), NF2 mutated mesothelioma and renal cancer, and other advanced solid tumors with relevant Hippo Pathway alterations.

The planned combination component will assess NXP900 with EGFR and ALK inhibitors in NSCLC patients who initially responded to these treatments but subsequently developed resistance.

NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, designed to inhibit both the catalytic and scaffolding functions of the SRC kinase.

"We believe that NXP900 represents a unique ’pipeline in a pill’ opportunity with the potential to address several substantial areas of unmet medical need in oncology," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, in the press release statement.

The company will hold a conference call on Tuesday, August 12 at 8:30 AM ET to discuss the Phase 1b program and market opportunity for NXP900.

Nuvectis Pharma is a clinical stage biopharmaceutical company focused on developing precision medicines for oncology. The company’s portfolio includes two clinical-stage drug candidates, NXP900 and NXP800.

In other recent news, Nuvectis Pharma announced it will halt further development of its NXP800 drug candidate for recurrent, platinum-resistant, ARID1a-mutated ovarian cancer. This decision follows a Phase 1b study involving 17 patients, which showed some clinical activity but also identified thrombocytopenia as a key toxicity. Meanwhile, Nuvectis has shifted its focus to NXP900, reporting a positive drug-drug interaction study for this cancer drug candidate. The study classified NXP900 as a weak inhibitor of the CYP3A enzyme, suggesting its potential use in combination with existing treatments for non-small cell lung cancer. Additionally, H.C. Wainwright adjusted its price target for Nuvectis Pharma to $10, down from $15, while maintaining a Buy rating. This adjustment reflects the removal of NXP800 from the firm’s projections and a focus on U.S. opportunities for NXP900. These recent developments indicate a strategic pivot for Nuvectis Pharma, emphasizing the potential of NXP900 in cancer treatment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.